The imposition of tariffs by the United States government has introduced significant uncertainties across various industries, including biotechnology. This white paper examines the potential ramifications of these tariffs on biotech manufacturing, funding, and the localization of clinical trials. Additionally, it evaluates whether there is a discernible trend toward conducting more clinical trials in Europe.
White Paper
The Potential Impact of U.S. Tariffs on the Biotech Sector: Manufacturing, Funding, and Clinical Trials
Download PDF
Related Resources
All Resources

post
Protecting Clinical Trial Supply Chains from Geopolitical Risk
Read More

white-paper
Commissioner’s National Priority Voucher (CNPV) Pilot Program
Read More

post
Digital QMS & Emerging AI Tools in Pharmaceutical Quality Management
Read More

infographic
What You Should Know About the FDA’s New CNPV Pilot Program
Read More
Let's move from science to success.
Let’s Talk
